Showing results (91-100 of 106) with videos related to
Sort By:
Pageof 11
AJP Reports|March 29, 2017
Massive Urinary Protein Excretion Associated with Greater Neonatal Risk in PreeclampsiaJulio Mateus, Roger Newman, Baha M Sibai, et al.American Journal of Obstetrics & Gynecology MFM|February 16, 2023
Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trialRichard Porreco, Thomas J Garite, C Andrew Combs, et al.AJP Reports|May 3, 2019
Cervical Pessary versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women with Placenta Previa: A Randomized Controlled TrialIrene A Stafford, Thomas J Garite, Kimberly Maurel, et al.BJOG : an International Journal of Obstetrics and Gynaecology|April 20, 2023
Progestogen maintenance therapy for prolongation of pregnancy after an episode of preterm labour: A systematic review and meta-analysisSofie H Breuking, Annemijn A De Ruigh, Frederik J R Hermans, et al.American Journal of Obstetrics and Gynecology|May 17, 2015
17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trialC Andrew Combs, Thomas J Garite, Kimberly Maurel, et al.Journal of Medical Screening|September 13, 2019
Evaluation of a novel screening method for fetal aneuploidy using cell-free DNA in maternal plasmaRichard P Porreco, Matthew Sekedat, Allan Bombard, et al.American Journal of Obstetrics and Gynecology|April 15, 2014
Removal versus retention of cerclage in preterm premature rupture of membranes: a randomized controlled trialAnna Galyean, Thomas J Garite, Kimberly Maurel, et al.American Journal of Obstetrics and Gynecology|November 27, 2013
Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranesC Andrew Combs, Michael Gravett, Thomas J Garite, et al.The Journal of Pharmacology and Experimental Therapeutics|November 12, 2017
INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid MalignanciesNiu Shin, Yun-Long Li, Song Mei, et al.Molecular Cancer Therapeutics|May 18, 2005
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicityCharles F Albright, Nilsa Graciani, Wei Han, et al.Pageof 11